China’s biopharmaceutical sector is off to a strong start in 2026, with record cross-border out-licensing activity and a growing pipeline of homegrown innovative drugs signaling the country’s rising role in the global biotech landscape. Data from the National Medical Products Administration showed that the total value of China’s out-licensing deals for innovative drugs exceeded USD60 billion in the first three months of 2026. The figure already amounts to nearly half of the USD135.7 billion recorded for the whole of 2025. An official from the regulator said that China’s innovative drug sector had achieved “historic breakthroughs” and was off to a strong start for the 15th Five Year Plan period (2026-30). The surge in out-licensing deals reflects growing international confidence in China’s research capabilities. Under such arrangements, Chinese pharmaceutical companies license the exclusive rights of drug candidates or technology platforms to global partners in exchange for upfront payments, milestone fees and future sales royalties. One of the quarter’s largest deals came from Hebei province-based CSPC Pharmaceutical Group, which signed a multi-project collaboration with AstraZeneca in January to jointly develop long-acting peptide drugs discovered using CSPC’s sustained-release drug delivery platform and AI-powered peptide discovery technology. Pascal Soriot, CEO of AstraZeneca, said in an earlier interview with China Daily that such partnerships illustrate the rapid rise of China’s biotech sector.
Other deals during the quarter highlight a similar trend toward deeper collaboration. According to industry database provider PharmCube, Chinese drugmakers signed more than 150 out-licensing agreements in 2025, with total deal value more than doubling from the previous year. Analysts at China Galaxy Securities say the structure of these transactions is evolving from single-asset licensing toward broader platform partnerships as global pharmaceutical companies seek access to China’s increasingly competitive discovery capabilities. The industry’s momentum is also reflected in corporate earnings. More than 70% of Chinese biopharmaceutical firms that disclosed 2025 results reported profits, while many innovators posted triple-digit earnings growth, suggesting out-licensing income and commercialization are beginning to offset years of heavy research spending.
Policy support is further reinforcing the sector. The 2026 Government Work Report identified biopharmaceuticals as an emerging pillar industry for the first time, placing it alongside integrated circuits, aviation and aerospace, and the low-altitude economy. Regulatory reforms are also expected to strengthen incentives for innovation. A revised regulation implementing the country’s drug administration law will take effect on May 15, introducing measures including six-year regulatory data protection, seven-year market exclusivity for rare-disease drugs, and additional incentives for pediatric medicines, a move analysts say could improve the country’s attractiveness for global drug development partnerships, the China Daily reports.
